#1MediPharm Labs Global Leader in Purified Cannabis Concentrates TSX-V: LABS Management Presentation December 2018 www.medipharmlabs.com FOR MALE extraktLAB abvancop eXTRACTION SYSTEMS INTE #Ivanco 3#2abv EXTRAC F Disclaimer December 2018 This presentation was prepared by management of MediPharm Labs Corp. ("MediPharm Labs"). The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in MediPharm Labs, and (c) is not to be considered as a recommendation by MediPharm Labs that any person make an investment. Any investment in the securities of MediPharm Labs is speculative and involves a number of risks that should be considered by any prospective investor. - This presentation does not constitute an offer or solicitation in any jurisdiction to any person or entity and was not prepared in connection with any such offer or solicitation. Readers of this presentation should not construe the contents of this presentation as legal, investment, tax or other advice. CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION MediPharm Labs cautions that statements in this presentation (including any oral commentary that may accompany it) are forward-looking statements. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our future results of operations or financial condition, prospects, business strategy and plans and objectives of management for future operations, the success of our sales and marketing efforts, the extent of market acceptance for our products and services, our ability to develop and bring to market new or enhanced products, our ability to develop our production facility, our international ventures, the cannabis and cannabis industry and regulatory environment and continuing uncertainty in the global economic environment, are forward-looking statements. The words "believe," "will," "may,” “estimate," "continue," "projection", "anticipate," "intend," "should," "plan," "expect," "predict," "could," "potentially" or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results and trends in the future may differ materially from those suggested or implied by the forward-looking statements depending on a variety of factors. The forward-looking statements contained in this presentation speak only as of the date the statements are made and are based on information available to the MediPharm Labs at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Such statements ar based upon the current beliefs and expectations of MediPharm Labs' management and are subject to significant business, social, economic, political, regulatory, competitive and other risks, uncertainties, contingencies and other factors. Many assumptions are based on factors and events that are not within the control of MediPharm Labs. Actual future results may differ materially from historical results or current expectations. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking information contained in this presentation, those results or developments may not be indicative of results or developments in subsequent periods. Although MediPharm Labs has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward- looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Forward- looking information contained in this presentation is based on MediPharm Labs' current estimates, expectations and projections, which MediPharm Labs believes are reasonable as of the current date. MediPharm Labs can give no assurance that these estimates, expectations and projections will prove to have been correct. You should not place undue reliance on forward-looking information, which is based on the information available as of the date of this presentation. Forward-looking information contained in this presentation is as of the date of this presentation and, except as required by applicable law, the Company assumes no obligation to update or revise them to reflect new events or circumstances. Historical statements should not be taken as a representation that such trends will be replicated in the future. No statement in this presentation is intended to be nor may be construed as a profit forecast. Additional information related to MediPharm Labs, including risks and uncertainties, can be found on its SEDAR profile at www.sedar.com. MediPharm Labs | 2#3Global Leader in Purified Cannabis Concentrates Why Invest? Leadership position in the specialization of Cannabis Oil Extraction in Canada Current capacity equivalent to $550M - $1B Potential Retail Revenue, ramping up to $1.4B by Q2/19(¹) Cannabis Oil is high margin, high growth segment of the Cannabis Market Significant Oil volume successfully processed to date with meaningful inventory build Meaningful barriers to entry (technology, expertise licensing and scale) Multiple significant signed sales agreements in place and actively completing delivery, Strong pipeline of new business 1. Potential retail revenue is not reflective of future revenue guidance or management expectations for actual financial results. Pricing reflects retail pricing to end consumer in Canadian market inclusive of excise tax of approximately 10%. 100,000kg (dried cannabis) Operating Annual Capacity 250,000kg capacity expected by Q2/19 Material revenue realization underway in fiscal 2018 set to scale rapidly in 2019 MediPharm Labs | 3#4Differentiated Extraction-Only Business Model: A Significant Competitive Advantage FIRST and ONLY Canadian LP under ACMPR exclusively focused on Cannabis Oil extraction ➤ Largest wholesale transaction for Cannabis Oil publicly announced to date ➤ Unrivaled production standards at our Ontario facility in the Golden Horseshoe - Canada ISO 14644 standard for Clean Rooms Built to exceed domestic and International CGMP standards • Built to exceed the standards of all 40+ legal jurisdictions globally ➤ ONLY Canadian LP with an active sales and production license solely for Cannabis Oil ➤ Leading technology, exceptional management and experienced operations team Current operations staff including processing, marketing, R&D, management of 60 International Growth strategy including a new Australian facility under development to same standards. Will act as import export hub and allow access Asia Pacific markets MediPharm Labs | 4#5Exceptional Leadership Team with Deep Experience Pat McCutcheon President & CEO 15-year career in pharmaceutical sales & marketing for a wide range of products. Recently led the Hospital Division for Renal and Mental Health products at Janssen Pharmaceuticals (J & J). Ahmed Shehata General Counsel & Head of Corporate Dev 10 years in Business Law focused on securities, mergers and acquisitions, and corporate finance. Previously counsel for numerous cannabis companies and going public transactions. Warren Everitt Managing Director, MediPharm Labs Australia Warren brings senior leadership in Asia Pacific through his international digital marketing agency, and career in sales & marketing, consulting to some of the world's biggest companies. David Mayers Chief Operating Officer 28 years of pharmaceutical leadership in multi- national and small organizations. Experienced in management of Controlled Substances, R&D, Quality, Lean Sigma, Supply Chain and strategy. Sybil Taylor Chief Marketing Officer 25-year marketing career in consumer-packaged goods. Experienced in strategic brand & product development and fully integrated communications in regulated alcohol & cannabis industries. eshop Laura Lepore VP Investor Relations & Communications Award winning Investor Relations and Communications Executive experienced in corporate and financial communications, public relations and capital markets for global organizations. Keith Strachan VP Business Development A Healthcare business development expert, bringing Supply Chain Management experience from gov't ministries, and consultancy in Public Sector RFP's, compliance, licensing & planning. Chris Hobbs Chief Financial Officer 18-year career in Finance, Chris has acted as Chief Financial Officer for several private and public companies operating in the resource, health sciences and technology sectors. wewew Jason Nalewany VP Finance A CPA-CA with cannabis experience, Jason has provided financial expertise to public entities in capital market strategies, M&A advisory, valuation, financial forecasting & due diligence. MediPharm Labs | 5 MAPAPAN#6Market Opportunity: Growing Demand For Cannabis Oil 5,000 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Canadian Medical Cannabis Sales (kg) Source: Health Canada, Market Data 2017-2018 m Apr. May Jun. Jul. Aug. Sept. Oct. Nov. Dec. Jan. 2017 2018 dried cannabis oil Feb. Mar. Apr. May Linear (oil) Jun. Oil sales have grown 92% in the last year while flower has grown only 18% MediPharm Labs | 6#7Market Opportunity: Retail Revenue Potential Sensitivity Based on Current 100,000kg Operational Funded Annual Capacity Increasing to 250,000kg Facility Capacity (Flower) Capacity Utilization Process Throughput (Flower) Flower to active cannabinoid conversion (Note A) Active Cannabinoid Content Active Cannabinoid Content Price per Active Component (Note B) [kg] [%] [kg] [%] [kg] [mg] M 100,000 50% 50,000 10% 5,000 5,000M $0.11 100,000 100% 100,000 10% 10,000 10,000M $0.11 250,000 50% 125,000 10% 12,500 12,500M $0.11 [mg] Revenue at retail per annum [$] B $0.550B $1.0B $1.37B a) Cannabinoid recovery from flower ranges between 10%-20%; Active cannabinoid concentration in crude ranges from 70% -80% b) Source: Based on aggregated pricing data per mg on Harvest Medicine website: https://hmed.ca/pricewatch/ ranging between $0.10 - $0.12 per mg. Potential retail revenue is not reflective of future revenue guidance or management expectations for actual financial results. Pricing reflects retail pricing to end consumer in Canadian market inclusive of excise tax of approximately 10%. MediPharm Labs | 7#8Unique 1st MOVER: MediPharm ahead of Extraction Pack Growth Company with a Valuation Re-Rate Opportunity Health Canada Oil Production Licence Health Canada Oil Sales Licence Canadian Licensed Cultivator Partnerships Current Market Cap* MediPharm (TSX-V:LABS) Granted March 2018 Granted November 2018 9 supply agreements + 5 processing agreements + 2 sales agreement $135.6M Neptune (TSX:NEPT) Application Pending *Approximate non-diluted Market Cap as of close of trading on December 7, 2018 N/A 1 invested $321.9M Radient (TSX-V:RTI) Application Pending N/A 1 invested $211.9M CuraLeaf (CNX:CURA) Application Pending N/A 1 partnership in Canada $2,195.0M MediPharm Labs | 8#9PHASE 1 - BUILT & OPERATIONAL ➤ Owned 70,000sq ft facility with interior modular design to accommodate significant processing expansion ➤ Phase 1 Manufacturing Facility - 100,000kg (dried cannabis) annual capacity 10,000 sq ft of pharma-grade manufacturing ● State-of-the-Art Facility Operational & Producing Purified Cannabis Oil ● ● ● 3 PRIMARY EXTRACTION lines Licensed & operational since April 2018 Daily avg Cannabis resin production of 10kg Concentrated to Avg 75% active cannabinoid in extracted resin Bench scale Distillation & Chromatography R&D Currently running 2 production shifts daily with a staff of ~25 quality & extraction technicians PHASE 2 - EXPANSION UNDERWAY ➤ Adding an additional 150,000kg (dried cannabis) annual capacity to existing facility 2 additional larger volume EXTRACTION LINES 2 industrial scale DISTILLATION SYSTEM 1 industrial scale COLUMN CHROMATOGRAPHY ► Phase 2 Expansion ● ● ● Leverages Phase 1 existing infrastructure Fully Funded & Expected online H2 2019 10,000 sq ft licensed space and development underway ► Significant additional space for future development MediPharm Labs | 9#10Largest Cannabis Oil LP Licensed Footprint in Canada Operational and Scalable Phase 1: 100,000kg annual capacity - 10,000 sq ft built and operational Phase 2: Additional 150,000kg annual capacity expected to be completed by end of Q2 2019 Phase 3: Ancillary Area As new cannabis products are approved Phase 4: Processing area for Licensed Partner 100,000kg of Annual Dry Cannabis Processing Licensed and equipped this phase has 2 production lines and over built support infrastructure. Operational Additional 35,000sq/f Processing Area Located in existing building, available for licensing. W D Additional 150,000kg of Annual Dry Cannabis Processing Licensed space. Custom extractor ordered (largest in Canada) utilizing Phase 1 infrastructure. L---- Ancillary Expansion Unlicensed space to be licensed for new cannabis products, as approved. Non-Cannabis Support Unlicensed space. To be used for non- cannabis operations, storage and shipping (2 existing docks). MediPharm Labs | 10#11THC CBD ● ● Deep Operational Expertise and Scientific Approach To Extraction Industry leading expertise in the production of pharma-grade cannabis concentrates Proprietary methodologies and operational efficiencies leveraged to build a growing library of purified concentrates and distillates. Utilizing Supercritical CO2 Extraction process. Operations specialists with deep expertise in cannabis extraction, complemented by years of pharmaceutical production experience to GMP standards Adjunct cannabis consultants provide additional knowledge from their home markets California Derivative Product specialist (adult-use since Jan 2018 - 150 allowable products) 20+ years Chromatography Expert from UK associated with German Equipment Manufacturer 50 years Extraction Expert with world-renown leading in-house research & training ● ● MediPharm Labs | 11#12Exceptional Operations Team - Research-Driven Operational Expertise Dr. Chris Talpas Director of Quality Control & Assurance A Chromatography expert with 24-years in the bio- pharmaceutical field. Deep experience in the qualification/validation of complex quality systems, processes & equipment. Dr. Ina Dubinsky Lead Scientist - Secondary Processing Experienced in R&D, testing & extraction of cannabis/hemp, isolation & purification of cannabinoids by vacuum distillation/filtration and RF column chromatography within FDA/GMP. Lorna Willner Director of Human Resources Lorna has a 25-year career as a collaborative leader developing best practices in recruitment, onboarding and coaching to build high performing teams aligned to company goals and values. Saravan Subramaniam Director, Project Management Office Saravan has expertise leading engineering and technical services projects in the pharmaceutical and automotive industries including product launches & complex manufacturing facility designs. 1943 Paul Hamelin Director of Security Paul has a 35-year career in policing. He is the Exec Director of Ontario Police Technology Information Co- 'operative and former president of the Ontario Association of Chiefs of Police. Anuja Siwakoti Director of Global Regulatory & Scientific Affairs Anuja is a senior leader in cannabis research, academia and regulated cannabis consulting, specializing in GPP/GMP audits, Health Canada licensing and navigating global regulations. Michael Perron Director of Global Business Development A CPA with a MAcc, Mike has spent over 10 years in professional services focused in Management Consulting, Enterprise Risk, and Transaction Advisory Services, leading the national cannabis practice. Dr. Jake Golding Director of Quality - Australia 20-years in bio-tech, with expertise in chemistry, commercial production & operations as well as quality systems. Experience includes registration & qualification of facilities, processes & equipment. MediPharm Labs | 12 w#13Extraction Focus Supports 2 Distinct Revenue Streams Mix Supports Higher Asset Utilization WHITE LABEL PRODUCTION SUPPLY AGREEMENTS (DRIED CANNABIS "IN") LABS purchases dried cannabis (flower/trim) from LP under Supply Agreement under X term or Y Volume LABS purchases dried cannabis via One-off Bulk Wholesale Supply Agreement इ SALE AGREEMENTS (CANNABIS OIL "OUT") Receive dried cannabis (flower/trim) from qualified Health Canada- and Office of Drug Control Australia-approved LPs Extract/purify/concentrate cannabis oil & return to LP. Agreements can extend to packaging & distribution Collect tolling fee for service Offtake agreements Expect to get to 80% White Label Production as Regulatory Environment evolves (Current mix is 50/50) ● Extract, purify & formulate to specifications of LP customers Sell purified concentrates &/or finished products at wholesale price to LPs CONTRACT PROCESSING LPs retail to patients or consumers under their brand $ CANNABIS CONCENTRATE PROGRAM AGREEMENTS MediPharm Labs | 13#14Significant Sales And Processing Agreements Completed Delivery Underway 180,000g of cannabis oil ready to ship Q4 2018 WHITE LABEL PRODUCTION SUPPLY AGREEMENTS (DRIED Cannabis IN) Supreme. TSXV: FIRE UP Cannabis CRONOS GROUP Additionally, several one-off bulk wholesale purchases have been completed from other LPs. ● $ SALE AGREEMENTS (Cannabis Oil Out) CANOPY GROWTH CORPORATION 18-month term contracted 450kg cannabis oil + optional up to 450kg = total up to 900kg In discussion with other LP's for additional one-off bulk wholesale oil sales agreements CONTRACT PROCESSING € CANNABIS CONCENTRATE PROGRAM AGREEMENTS OUR JWC James & Wagner ROOTS Ν RUN Supreme. TSXV: FIRE e emerald™ HEALTH THERAPEUTICS DEEP BONIFY™ MediPharm Labs | 14#15MediPharm Labs CANOPY GROWTH TIY CORPORATION Significant Cannabis Oil Sale Agreement with Canopy Growth Corporation ● ● ● ● First sale to world's largest cannabis company demonstrates strong endorsement of MediPharm's specialized extraction model MediPharm will refine its own inventory of dried flower into high quality cannabis oil extract for sale to Canopy Growth Agreement is for an initial purchase commitment of 450kg and additional purchase options for 450kg, for total volume of up to 900kg of cannabis oil extract First instalment of committed purchase of cannabis oil extract to be delivered by the end of fiscal Q4 2018 Balance of oil purchase commitments are scheduled to occur monthly through 2019. Additional purchase options available from January 2019 through mid-2020 Agreement represents less than 5% of MediPharm's expected annual processing capacity of approximately 250,000 kg scheduled to be completed end of Q2 2019 Significant excess capacity to fulfill the role as an agnostic supplier of pharma-grade cannabis oil concentrates to the global cannabis industry MediPharm Labs | 15#16International Growth Strategy First Move: Australia and Asia Pacific Growth strategy to expand to Australia provides ability to service Asia Pacific markets Actively engaging in opportunities to commence importing and exporting of medical cannabis where federally permissible MediPharm Labs is majority holder (80%) of subsidiary MediPharm Labs Australia Pty. Ltd. Land has been purchased and construction is underway at the MediPharm Labs Australia facility, the first step in the Company's international growth strategy. MediPharm Labs Australia working with 25 Cultivation partners providing options for significant supply inputs Manufacturing licence application currently being reviewed by the Australian Office of Drug Control. Facility is expected to be operational in H2 2019 pending licensing Australia site expected to act as an import and export hub, subject to licensing, until such time as Australian domestic-patient-demand warrants dedicated production activities, 1 hour south-east of Melbourne Corporate Organizational Chart MEDIPHARM LABS CORP. (ON) PUBLICLY TRADED COMPANY MEDIPHARM LABS INC. (ON) LICENSED COMPANY 100% 100% MPL PROPERTY HOLDINGS INC. (ON) HOLDING PROPERTY 80% MEDIPHARM LABS AUSTRALIA PTY. LTD. (AUSTRALIA) MediPharm Labs | 16#17International Growth Strategy First Move: Australia Facility: Wonthaggi, Victoria expected operational in H2 2019 pending licensing til-Au DANGER S chon Mar O MediPharm Labs MediPharm Labs | 17 MediPharm Labs ARTIST IMPRESSION#18Global Leader in Purified Cannabis Oil Leaders in Cannabis Oil Extraction Operating in High margin, high growth segment of Cannabis Investment Summary Meaningful barriers to entry (technology, expertise licensing and scale) One of the largest extraction footprints in Canada Phase I (completed) manufacturing capacity to extract over 100,000 kg of dry cannabis annually Phase II (Est. Q2 2019) capacity to extract an additional 150,000 kg dry cannabis Significant Retail Revenue Potential Meaningful inventory build Significant sales agreements Strong pipeline of new business Material revenue realization underway in fiscal 2018 set to scale rapidly in 2019 Differentiated Extraction-Only Business Model FIRST and ONLY Canadian LP under ACMPR exclusively focused on Cannabis Oil extraction A Competitive Advantage Significant wholesale transaction for Cannabis Oil with Canopy Growth Secure Supply - Bulk Purchases: wholesale purchases from 9 LP's Processing Agreements: multi-year contracts signed with 5 LP's while negotiating multiple others Licenses: March 2018: ACMPR Oil Production Licence November 2018: Health Canada Sales Licence Pending: Australia Office of Drug Control to extract and import medical cannabis Economies of scale through large volume production and automation. Purchasing power through large scale buying Exceptional Leadership & Deep Operating Expertise Senior team with deep experience in global bio-pharmaceutical, healthcare, energy, and biotechnology manufacturing Director of Quality Assurance renowned Chromatography expert with 24-years in big Pharma qualifying/validating complex quality systems, processes & equipment Manufacturing and distribution partnerships with proven, patented formulators from other global cannabis jurisdictions Built to Exceed International Quality Standards Laboratory and manufacturing facilities purpose-built to Global CGMP standards with ISO rated pharma-grade clean rooms & critical environments. Meet or exceed standards of all cannabis markets. Allows for export globally Team with experience in Six Sigma Lean Manufacturing R & D partner on extraction technology, formulation development, commercialization of products with leading, accredited teaching hospitals, college and universities International Growth Growth & Strategy Valuation Re-Rate Growth strategy to expand to Australia provides ability to service Asia Pacific markets Actively engaging in opportunities to commence importing and exporting of medical cannabis where federally permissible 25 Australian Cultivation partners providing options for significant supply inputs Australia site expected to act as an import and export hub, subject to licensing, until such time as Australian domestic-patient-demand warrants dedicated production activities, 1 hour south-east of Melbourne TSX-V: LABS Price: $1.39/share* Market Cap: $135.6M* Issued & Outstanding: 97.5M Warrants & Options: 35.5M Fully Diluted: 133M Concurrent Financing: over- subscribed by 48.6% to $22.3M Based on market close December 7, 2018 MediPharm Labs | 18#19Please Contact for Additional Information Pat McCutcheon, President and Chief Executive Officer Laura Lepore, Vice President, Investor Relations & Communications [email protected] Phone +1 705 719 7425 ext. 216 www.medipharmlabs.com TSX-V: LABS in /medipharm-labs @medipharmlabs. D @medipharmlabs f @medipharmlabs MediPharm Labs | 19#20Appendix oršiamy (145 extraktLAB 1 advancop eXTRACTION SYSTEMS MediPharm Labs Elvanco#21Company Capital Structure - Post-RTO Capital Structure Common Shares Options with exercise price of $1.68 per Common Share Options with exercise price of $0.2366 per Common Share Options with exercise price of $0.20 per Common Share Broker Warrants with exercise price of $0.20 per Common Share Warrants with exercise price of $1.20 per Common Share Broker Warrants with exercise price of $0.29, with each Broker Warrant comprised of one Common Share and one Warrant with an exercise price of $0.47 Warrants with an exercise price of $0.47 Broker Warrants with an exercise price of $0.85, with each Broker Warrant comprised of one Common Share and one half Warrant with each full Warrant having an exercise price of $1.20 97.5M 3.0M 5.9M 0.5M 0.07M 12.5M 0.6M 10.0M 1.51M $ 0.01M $ 15.1M $ 0.17M $ 0.28M $ 4.7M $ 1.3M $ 0.9M $ 22.4M TOTAL Potential Influx from Options & Warrants Non-diluted Ownership Breakdown on listing date: Management (35% ) Institution (19% ) Retail (46%) MediPharm Labs | 21#2266 DO WHAT YOU DO BESTAND OUTSOURCE THE REST Peter Drucker on Modern Business Practices 99 MediPharm Labs | 22#23MediPharm Labs Voted on by a judging committee, and chosen using these award criteria: This company exemplifies the qualities that define promising start-ups: plucky, innovative and creative. Its top-notch team identifies and solves industry problems and contributes beneficially to the cannabis sector at-large. CANADIAN CANNABIS AWARDS WINNER 2018 START-UP OF THE YEAR MediPharm Labs | 23#24True medical products are concentrate-based for precise dosing The Future of the Industry High-Margin Concentrates Leading the Cannabis Industry Whether for precisely dosed, consumer-safe medical or adult-use products, purified cannabis concentrates will be a base ingredient in high demand for all advanced derivative products. $ Oil delivers consistent high-margin products; with barriers to entry A During extraction and refinement, impurities are removed O Longer shelf stability vs. flower products CBD Physicians' preferred delivery method is smokeless Oil will be the base of future cannabis recreational products i.e. edibles, lotions, beverages Oil is the only allowable cannabis product in many countries MediPharm Labs | 24#25Secured Supply Agnostic Service Provider to Entire Industry MEDIPHARM LABS HAS ALREADY SECURED OVER 3200 KG IN DRY CANNABIS SUPPLY PRODUCT FOCUSED PARTNERSHIPS WITH LPS FIXED VOLUME CONTRACTS ONE-OFF BULK PURCHASES 700 Licensed Producers and Applicants; supply glut imminent MULTIPLE LICENSED CANNABIS SUPPLY INPUTS (FLOWER, TRIM, HEMP, OUTDOOR GROW, AGED INVENTORY) IDEAL PRODUCTION CAPACITY MediPharm Labs | 25#26Receive dry bud, trim & shake MILLING Vacuum Dry and DECARBOXYLATE Plant Material EXTRACT With Supercritical CO2 MediPharm Labs Extraction Processes Crude Extract 50% Light Terpene Fraction 1 WINTERIZE & FILTERED Wax & Lipids Ethanol Solvent ROTARY EVAPORATION Winterized Oil 60% Primary Extraction Crude Resin 75% Heavy Terpene Fraction 2 SHORT PATH DISTILLATION Residue Fraction 4 Secondary Processing Distillate 90% Cannabinoid Fraction 3 CENTRIFUGE CHROMATOGRAPHY Isolate 99.9% Cannabinoid Fraction 5 MediPharm Labs | 26#27MediPharm Labs Harnessing the potential in global cannabis through science-based leadership: A frontrunner in cannabis extraction and purification, MediPharm Labs has invested in an expert team, state-of-the-art technology, advanced proprietary methodologies and purpose-built facilities to deliver pure, safe and precisely dosable cannabis concentrates for advanced derivative products. We are an industry connector, simplifying and unifying the value chain as a trusted partner to those focused on cultivating or end-product manufacturing. !!!! OPEN PREF LL OPEN+ OPEN CLOSE CLOSE Extraction MediPharm Labs | 27